Cantor Fitzgerald Starts Galena Biopharma (GALE) at Buy; New Approach to Breast Cancer

Article Stock Quotes (1) Comments (0)

Cantor Fitzgerald initiates coverage on Galena Biopharma (NASDAQ: GALE) with a Buy. PT $4.00.

Analyst, Mara Goldstein, said, "alena is a phoenix of sorts, having shed early-stage assets in favor of later-stage clinical programs. The company is currently conducting a Phase III trial with NeuVax for the prevention of breast cancer recurrence in women with low HER2 expression and advancing a new candidate, FBP, to prevent recurrence of gynecological cancers. Both programs are novel and would represent major advances in prevention of disease."

For an analyst ratings summary and ratings history on Galena Biopharma click here. For more ratings news on Galena Biopharma click here.

Shares of Galena Biopharma closed at $1.29 yesterday, with a 52 week range of $0.36-$3.54.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
• Barclays Starts AT&T (T) at Equalweight
• Jefferies Starts Cempra, Inc. (CEMP) at Buy

Create E-mail Alert Related Categories

New Coverage

Related Entities

Cantor Fitzgerald

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?